A New Drug for Obesity: Tirzepatide

Jul 12, 2024Endocrine, metabolic & immune disorders drug targets

Tirzepatide as a New Treatment for Obesity

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Tirzepatide, a dual agonist of GIP and GLP-1 receptors, was recently approved for obesity management.

Obesity is recognized as a significant global public health issue with increasing incidence over the past two decades.
A comprehensive treatment approach for obesity may include behavioral therapy, medications, lifestyle changes, and bariatric surgery.
Tirzepatide has been shown to manage blood sugar levels effectively.
Tirzepatide may facilitate greater weight loss compared to existing GLP-1 receptor agonists.

AI simplified

Obesity is now recognised as an emerging public health problem across the globe. Its incidence has been growing in the last two decades. Furthermore, as per the obesity treatment guidelines, a comprehensive approach that incorporates behavioural treatment, medications, lifestyle modifications, and/or bariatric surgery is the best way to manage weight. A novel dual agonist of Glucose-dependent insulinotropic peptide (GIP) and Glucagon-like peptide -1 (GLP- 1) receptors, Tirzepatide, was recently approved for the management of obesity. Tirzepatide manages blood sugar levels and enhances weight loss more than GLP-1 receptor agonists.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗View full text ↗

A New Drug for Obesity: Tirzepatide

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief